[Recommended Interventions for the Treatment of Peripheral Artery Disease : Keep the Patients Moving]

Overview

Journal Internist (Berl)

Specialty General Medicine

Date 2019 Nov 1

PMID 31667527

Citations 1

Authors

H Krankenberg

Affiliations

Soon will be listed here.

Abstract

Background: Peripheral artery disease (PAD) is often diagnosed in an advanced stage. Accordingly, revascularization is also performed late.

Objectives: In this paper, the authors describe the progression to critical limb ischemia and cardiovascular risk. Revascularization for secondary prevention is explained. Revascularization strategies according to lesion location and complexity of the stenosis or occlusion are discussed.

Materials And Methods: The current guidelines and randomized controlled studies and meta-analyses are analyzed.

Results: PAD is associated with a considerable level of suffering and a high cardiovascular risk. Up to 20% of patients with claudicants will progress to critical limb ischemia. Progression and risk of mortality increase during the course of the disease. Improvement of walking ability by revascularization is a major goal of secondary prevention. In the femoropopliteal segment, drug-coated balloon (DCB) angioplasty and bare-metal stent (BMS) implantation are the methods of choice. In long lesions, spot-stenting should be preferred. For treatment of in-stent restenosis, DCB have proven their effectiveness. In severely calcified or dissected lesions, BMS are well suited. Infrapopliteal lesions should be revascularized to provide in-line flow to the foot through the target arterial path. According to current evidence, DCB or drug-eluting stents are more effective than plain old balloon angioplasty or BMS.

Citing Articles

Use of Oral Anticoagulation and Diabetes Do Not Inhibit the Angiogenic Potential of Hypoxia Preconditioned Blood-Derived Secretomes.

Moog P, Jensch M, Hughes J, Salgin B, Dornseifer U, Machens H Biomedicines. 2020; 8(8).

PMID: 32796694 PMC: 7459715. DOI: 10.3390/biomedicines8080283.

References

Taeymans K, Groot Jebbink E, Holewijn S, Martens J, Versluis M, Goverde P . Three-year outcome of the covered endovascular reconstruction of the aortic bifurcation technique for aortoiliac occlusive disease. J Vasc Surg. 2017; 67(5):1438-1447. DOI: 10.1016/j.jvs.2017.09.015. View

Dake M, Ansel G, Jaff M, Ohki T, Saxon R, Smouse H . Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial. Circulation. 2016; 133(15):1472-83. PMC: 4823823. DOI: 10.1161/CIRCULATIONAHA.115.016900. View

Zhou Y, Lin S, Zhang Z, Xiao J, Ai W, Wang J . A Network Meta-analysis of Randomized Controlled Trials Comparing Treatment Modalities for Infrapopliteal Lesions in Critical Limb Ischemia. Ann Vasc Surg. 2019; 60:424-434. DOI: 10.1016/j.avsg.2019.02.021. View

Aboyans V, Ricco J, Bartelink M, Bjorck M, Brodmann M, Cohnert T . 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric,.... Eur Heart J. 2017; 39(9):763-816. DOI: 10.1093/eurheartj/ehx095. View

Sartipy F, Sigvant B, Lundin F, Wahlberg E . Ten Year Mortality in Different Peripheral Arterial Disease Stages: A Population Based Observational Study on Outcome. Eur J Vasc Endovasc Surg. 2018; 55(4):529-536. DOI: 10.1016/j.ejvs.2018.01.019. View

Song P, Rudan D, Zhu Y, Fowkes F, Rahimi K, Fowkes F . Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019; 7(8):e1020-e1030. DOI: 10.1016/S2214-109X(19)30255-4. View

Piazza M, Squizzato F, DallAntonia A, Lepidi S, Menegolo M, Grego F . Editor's Choice - Outcomes of Self Expanding PTFE Covered Stent Versus Bare Metal Stent for Chronic Iliac Artery Occlusion in Matched Cohorts Using Propensity Score Modelling. Eur J Vasc Endovasc Surg. 2017; 54(2):177-185. DOI: 10.1016/j.ejvs.2017.03.019. View

Muller-Hulsbeck S, Keirse K, Zeller T, Schroe H, Diaz-Cartelle J . Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up. Cardiovasc Intervent Radiol. 2017; 40(12):1832-1838. DOI: 10.1007/s00270-017-1771-5. View

Werner M, Paetzold A, Banning-Eichenseer U, Scheinert S, Piorkowski M, Ulrich M . Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: midterm results from the Leipzig SUPERA 500 registry. EuroIntervention. 2014; 10(7):861-8. DOI: 10.4244/EIJV10I7A147. View

10.

Jia X, Sun Z, Patel J, Flood K, Stocken D, Scott D . Systematic review of endovascular intervention and surgery for common femoral artery atherosclerotic disease. Br J Surg. 2018; 106(1):13-22. DOI: 10.1002/bjs.11026. View

11.

Nguyen B, Amdur R, Abugideiri M, Rahbar R, Neville R, Sidawy A . Postoperative complications after common femoral endarterectomy. J Vasc Surg. 2015; 61(6):1489-94.e1. DOI: 10.1016/j.jvs.2015.01.024. View

12.

Ichihashi S, Shibata T, Fujimura N, Nagatomi S, Yamamoto H, Kyuragi R . Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement. J Endovasc Ther. 2019; 26(5):613-620. DOI: 10.1177/1526602819860124. View

13.

Fowkes F, Aboyans V, Fowkes F, McDermott M, Sampson U, Criqui M . Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol. 2016; 14(3):156-170. DOI: 10.1038/nrcardio.2016.179. View

14.

Cassese S, Wolf F, Ingwersen M, Kinstner C, Fusaro M, Ndrepepa G . Drug-Coated Balloon Angioplasty for Femoropopliteal In-Stent Restenosis. Circ Cardiovasc Interv. 2018; 11(12):e007055. DOI: 10.1161/CIRCINTERVENTIONS.118.007055. View

15.

Krankenberg H, Zeller T, Ingwersen M, Schmalstieg J, Gissler H, Nikol S . Self-Expanding Versus Balloon-Expandable Stents for Iliac Artery Occlusive Disease: The Randomized ICE Trial. JACC Cardiovasc Interv. 2017; 10(16):1694-1704. DOI: 10.1016/j.jcin.2017.05.015. View

16.

Rosenbloom M, Flanigan D, Schuler J, Meyer J, DURHAM J, Schwarcz T . Risk factors affecting the natural history of intermittent claudication. Arch Surg. 1988; 123(7):867-70. DOI: 10.1001/archsurg.1988.01400310081013. View

17.

Indes J, Pfaff M, Farrokhyar F, Brown H, Hashim P, Cheung K . Clinical outcomes of 5358 patients undergoing direct open bypass or endovascular treatment for aortoiliac occlusive disease: a systematic review and meta-analysis. J Endovasc Ther. 2013; 20(4):443-55. DOI: 10.1583/13-4242.1. View

18.

Abaraogu U, Ezenwankwo E, Dall P, Seenan C . Living a burdensome and demanding life: A qualitative systematic review of the patients experiences of peripheral arterial disease. PLoS One. 2018; 13(11):e0207456. PMC: 6237376. DOI: 10.1371/journal.pone.0207456. View

19.

Fusaro M, Cassese S, Ndrepepa G, King L, Tada T, Ott I . Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: a meta-analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison. Int J Cardiol. 2013; 168(4):4002-9. DOI: 10.1016/j.ijcard.2013.06.081. View

20.

Kayssi A, Al-Jundi W, Papia G, Kucey D, Forbes T, Rajan D . Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries. Cochrane Database Syst Rev. 2019; 1:CD012510. PMC: 6353053. DOI: 10.1002/14651858.CD012510.pub2. View